SCHEMBL6407534

SCHEMBL6407534

CC(CO)N(C)S(=O)(=O)c1ccc(-c2cccs2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
MMP2 P08253 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
ADAMTS4 O75173 1/20 0.42
LTA4H P09960 1/20 0.39
PTGS2 P35354 1/20 0.39
PTPN22 Q9Y2R2 1/20 0.38
FFAR1 O14842 1/20 0.38
PSMB5 P28074 1/20 0.38
SCD O00767 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
STAT3 P40763 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324715 0.87 CA12 (0.42) CA12CA1CA2MMP2CA9
SCHEMBL6323686 0.80 ADAMTS4 (0.62) MMP2ADAMTS4PKMADAMTS5MMP12
SCHEMBL6323684 0.80 ADAMTS4 (0.62) MMP2ADAMTS4PKMADAMTS5MMP12
SCHEMBL7053207 0.78 KDM4E (0.50) CA12CA1CA2MMP2CA9
SCHEMBL6324353 0.76 KCNH2 (0.45) CA12CA1CA2MMP2CA9
SCHEMBL6321475 0.75 ESR1 (0.49) ADAMTS4MEN1KMT2AHPGDALDH1A1
SCHEMBL6321479 0.75 ESR1 (0.49) ADAMTS4MEN1KMT2AHPGDALDH1A1
SCHEMBL6322299 0.75 MMP2 (0.62) CA12CA1CA2MMP2CA9
SCHEMBL6325881 0.74 PSEN1 (0.52) CA1CA2ADAMTS4MEN1KMT2A
SCHEMBL6325883 0.74 PSEN1 (0.52) CA1CA2ADAMTS4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 CA12 248/4885CA1 196/4885CA2 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.